Trial · NCT02237365
A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis
NCT02237365, Phase 2, Completed, Oxford University Clinical Research Unit, Vietnam
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis. Trials, record NCT02237365. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02237365
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis
- NCT number
- NCT02237365
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 120 participants, actual
- Lead sponsor
- Oxford University Clinical Research Unit, Vietnam
- Conditions
- Tuberculous Meningitis
- Interventions
- 81mg aspirin, 1000mg aspirin, Placebo
- First posted
- 2014-09-11
- Last updated
- 2017-03-07
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of episodes of either cerebral bleeding or clinically significant upper-gastro-intestinal bleeding (composite endpoint) | 60 days | Primary Safety Endpoint: Number of episodes of: 1. Cerebral bleeding confirmed by brain imaging and/or 2. Clinically significant upper-gastro-intestinal bleeding, defined as: a) Vomiting fresh or changed blood of any volume; b) Melena; c) Unexplained drop in haemoglobin concentration of \>2g/L or; d) Greater than 5mls of fresh or changed blood aspirated from nasogastric tube |
| Primary | Number of episodes of MRI-proven brain infarction or death (composite endpoint) | 60 days | Primary Efficacy Endpoint: Number of episodes of 1. MRI-proven brain infarction and/or 2. Death |
| Secondary | Time to death | 240 days | |
| Secondary | Number of grade 3&4 and serious adverse events | 60 days | Graded according to Common Terminology Criteria for Adverse Events (CTCAE) definitions |
| Secondary | Duration of hospital stay | 240 days | Number of days admitted to hospital during the study period |
| Secondary | Neurological disability score | 60 days | Assessed by the modified Rankin score and Glasgow outcome score |
| Secondary | Neurological disability score | 240 days | Assessed by the modified Rankin score and Glasgow outcome score |
| Secondary | Resolution of cerebrospinal fluid (CSF) inflammation | 30 days | Evaluated by measurement of CSF leucocytes, protein, glucose, cytokines (TNF-α, IL-1β, IL-8, IL-10, IFNγ) and eicosanoids (15-epi-Lipoxin, Lipoxin A4, LTB4, PGE2, TBXB2, PGD2) |
| Secondary | Antimicrobial activity of peripheral blood monocyte/macrophages | 240 days | Difference between measured antimicrobial activity at baseline and 240 days |
| Secondary | Proportion of patients with MRI-proven brain infarction | 240 days |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 29482717 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02237365
GET https://conductscience.org/api/trials/v1/NCT02237365/registered